Palvella Therapeutics (NASDAQ: PVLA) said it remains on track to complete its new drug application s

WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”

Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript

Palvella Therapeutics NASDAQ: PVLA said it remains on track to complete its new drug application sub

First module of the rolling NDA for QTORIN™ rapamycin for microcystic lymphatic malformations submit

Arete Wealth Advisors LLC purchased a new position in Palvella Therapeutics, Inc. (NASDAQ: PVLA) dur

Hybrid public meeting on August 5th will explore approaches to selecting and prioritizing promising

WAYNE, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc . (Palvella or the “Company

Fifth Third Bancorp bought a new stake in Palvella Therapeutics, Inc. (NASDAQ: PVLA) in the undefine

US stocks rise, Nasdaq gains 1%. Hasbro Inc (HAS) up 8.6% on strong Q2 results and raised sales guid

Brings more than 25 years of experience advancing and commercializing high-impact therapies for seri

FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evalu

4,302 common shares were exercised and sold on June 17, 2026, for $476,000 at a weighted average pri

FDA's rolling review process is intended to facilitate expedited review, enabling FDA to begin evalu

Palvella Therapeutics, Inc. (PVLA) Presents at Goldman Sachs 47th Annual Global Healthcare Conferenc

Palvella Therapeutics is now a much more credible bet on QTORIN after their positive mLM data. They'

Palvella remains on track to submit an NDA in the second half of 2026 Microcystic lymphatic malforma

WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”

Yale-licensed U.S. patent provides broad protection for topical mevalonate pathway inhibition in por

WAYNE, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”)

In SELVA Phase 3 study, 100% of participants (13/13) aged 6-11 years were rated as "Much Improved" (